Navigation Links
The MMRF and John Theurer Cancer Center to host patient symposium
Date:3/17/2011

NORWALK, C.T. and HACKENSACK, N.J. (March 16, 2011) The Multiple Myeloma Research Foundation (MMRF) and the John Theurer Cancer Center at Hackensack University Medical Center, member of the Multiple Myeloma Research Consortium (MMRC), will host the MMRF Clinical Insights in Multiple Myeloma Patient Symposium on Saturday, April 2 in Short Hills, NJ from 9:00am-3:30pm. This free educational program is for patients and caregivers who want to learn more about treatment options for multiple myeloma.

"As a result of the tremendous progress we have made accelerating the development of multiple myeloma treatments, patients are living longer and have more treatment options," said Anne Quinn Young, MPH, Vice President of Communications at the MMRF. "MMRF Clinical Insights programs aim to empower patients and their caregivers by arming them with the knowledge they need to optimally manage their disease. We are proud to join our partners at the John Theurer Cancer Center and other renowned institutions to host this important program."

Leading multiple myeloma experts will highlight the latest information in multiple myeloma diagnosis, treatment options, clinical trials and research. Topics to be discussed include treatment options for newly diagnosed patients, stem cell transplantation, relapsed/refractory disease, clinical trials, supportive care options, and managing bone disease.

"For nearly five years, we have worked closely with the MMRF through the MMRC, a unique research model critical to bringing new treatments to our patients faster," said David S. Siegel, M.D., Ph.D., Chief, Multiple Myeloma. "We are excited to take our collaboration with the MMRF outside of the clinic by developing content for this educational symposium, which will be a valuable resource for our patients and their loved ones."

Dr. Siegel and David H. Vesole, M.D., Ph.D., Co-Chief, Multiple Myeloma, John Theurer Cancer Center are serving as the official program co-chairs for this patient symposium. Additional presenters include:

  • Jonathan Kaufman, M.D., Assistant Professor, Blood & Marrow Transplantation, Emory University School of Medicine
  • Ann McNeill, RN, MSN, APN, Advanced Practice Nurse, Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center
  • Nikhil C. Munshi, M.D., Associate Director, Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute
  • G. David Roodman, M.D., Ph.D., Professor of Medicine and Vice Chair for Research, University of Pittsburgh School of Medicine

Following the symposium, attendees will also have the opportunity to participate in special workshop sessions with Dr. Siegel, Dr. Vesole and Ms. McNeill of the John Theurer Cancer Center. Workshop session topics include Multiple Myeloma 101, Maintenance Therapy and Interpreting Test Results.

"With so much exciting research and treatment options emerging, multiple myeloma patients and caregivers often feel overwhelmed," said Dr. Vesole. "It is our responsibility to keep the multiple myeloma community informed of our progress and how it will impact the management of their disease."

The symposium will be hosted at the Hilton Short Hills, 41 JFK Parkway, Short Hills, NJ on Saturday, April 2 from 9:00am-3:30pm. This program is free, however, space is limited. Online registration is available at themmrf.org/clinicalinsights. For additional information, special accommodations or meal requests please contact Sara Tyghter at 203.652.0219 or tyghters@themmrf.org.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
2. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
3. Oncology basic research director at John Theurer Cancer Center continues transplantation research
4. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
5. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
6. John Theurer Cancer Center to present innovative research at 2 surgical meetings
7. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
8. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
9. The John Theurer Cancer Center recognizes medical physics team for safety track record
10. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
11. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology: